- Home
- ACIU vs NAUT Comparison
ACIU vs NAUT Comparison
Compare ACIU & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- NAUT
- Stock Information
- Founded
- ACIU 2003
- NAUT 2016
- Country
- ACIU Switzerland
- NAUT United States
- Employees
- ACIU N/A
- NAUT N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- NAUT Biotechnology: Laboratory Analytical Instruments
- Sector
- ACIU Health Care
- NAUT Industrials
- Exchange
- ACIU Nasdaq
- NAUT Nasdaq
- Market Cap
- ACIU 319.6M
- NAUT 284.7M
- IPO Year
- ACIU 2016
- NAUT N/A
- Fundamental
- Price
- ACIU $3.21
- NAUT $2.87
- Analyst Decision
- ACIU Strong Buy
- NAUT Buy
- Analyst Count
- ACIU 2
- NAUT 2
- Target Price
- ACIU $12.00
- NAUT $4.50
- AVG Volume (30 Days)
- ACIU 83.8K
- NAUT 71.6K
- Earning Date
- ACIU 11-01-2024
- NAUT 10-29-2024
- Dividend Yield
- ACIU N/A
- NAUT N/A
- EPS Growth
- ACIU N/A
- NAUT N/A
- EPS
- ACIU N/A
- NAUT N/A
- Revenue
- ACIU $17,235,700.00
- NAUT N/A
- Revenue This Year
- ACIU N/A
- NAUT N/A
- Revenue Next Year
- ACIU $974.52
- NAUT N/A
- P/E Ratio
- ACIU N/A
- NAUT N/A
- Revenue Growth
- ACIU 293.60
- NAUT N/A
- 52 Week Low
- ACIU $2.20
- NAUT $2.19
- 52 Week High
- ACIU $5.14
- NAUT $3.46
- Technical
- Relative Strength Index (RSI)
- ACIU 39.43
- NAUT 54.02
- Support Level
- ACIU $3.17
- NAUT $2.62
- Resistance Level
- ACIU $3.39
- NAUT $3.03
- Average True Range (ATR)
- ACIU 0.16
- NAUT 0.12
- MACD
- ACIU -0.04
- NAUT 0.01
- Stochastic Oscillator
- ACIU 11.27
- NAUT 63.38
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.